GlassScriptPhysician profile
Frederick D Turpin
NPI 1376536029
$20,634.21
in general payments reported to CMS, 2019-2025
71 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,287 · 2020: $2,138 · 2021: $2,634 · 2022: $2,922 · 2023: $3,904 · 2024: $4,733 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,382 · Consulting Fee: $150 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,382.08 |
| Consulting Fee | $150.00 |
| Education | $120.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,584.74 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $1,277.30 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $1,271.20 | 2019-2024 | Qelbree |
| Sunovion Pharmaceuticals INC. | $1,231.72 | 2019-2022 | |
| Ucb, INC. | $1,070.26 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Biogen, INC. | $1,012.86 | 2019-2024 | Tysabri, Vumerity, Skyclarys |
| Pfizer INC. | $905.33 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $713.94 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $697.65 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Emd Serono, INC. | $678.71 | 2019-2024 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $655.61 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $608.23 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Sk Life Science, INC. | $464.54 | 2020-2025 | Xcopri |
| Amneal Pharmaceuticals LLC | $426.35 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Acadia Pharmaceuticals INC | $415.47 | 2019-2024 | Nuplazid |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Turpin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.